Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner

SILVIA WÜRSTLE1, FABIAN SCHNEIDER1, FLORIAN RINGEL2,3, JENS GEMPT2, FRIEDERIKE LÄMMER1, CLAIRE DELBRIDGE1, WEI WU1 and JÜRGEN SCHLEGEL1

Departments of 1Neuropathology and 2Neurosurgery, Technische Universität München, D-81675 Munich; 3Department of Neurosurgery, Universität zu Köln, D-55131 Mainz, Germany

Received September 2, 2016; Accepted January 13, 2017

DOI: 10.3892/ol.2017.6107

Abstract. Despite major contributions to the current molecular understanding of autophagy, a recycling process for intracellular components to maintain homeostatic balance, relatively little is known about the interacting networks. To address this issue, the current study investigated the role of autophagy in primary and established glioblastoma multiforme (GBM) cells and its interplay with the epidermal growth factor receptor (EGFR) and the standard chemotherapeutic agent temozolomide (TMZ). TMZ treatment leads to an upregulation of autophagy, predominantly in primary GBM cells. The interaction between EGFR and Beclin-1, an important protein in initiating autophagy, was assessed using a cancer cell line transfected with EGFR and by stimulation with EGF. The results of the current study suggest that Beclin-1 and EGFR do not interact directly in either primary or established GBM cells. To enable the limited efficacy of patient treatment strategies of GBM to potentially be enhanced through the application of autophagy regulators, the multiple cellular interactions of autophagy require further elucidation.

Introduction

Glioblastoma multiforme (GBM) is not only the most common type of brain tumor in adulthood, but also one of the most malignant types of cancer, with a median survival time (World Health Organization grade IV) of 14-15 months with maximum treatment (1). Its infiltrative and heterogeneous characteristics, combined with high proliferation rates, makes treatment challenging. Standard therapy includes surgery, adjuvant radiotherapy and chemotherapy with the alkylating agent temozolomide (TMZ) (1). TMZ was first identified by Stevens et al in 1984 (2) as an oral anti-cancer treatment. The active metabolite of TMZ methylates guanine residues in the DNA, leading to double strand breaks (3). The O6-methylguanine-DNA methyltransferase (MGMT) gene codes for a protein that removes the methylation performed by TMZ and abrogates its effects (4). This gene's promoter is methylated in ~50% of cases, which is an independent and favorable prognostic factor for patients with GBM (4).

Previous studies have established the association between chemotherapy with TMZ and autophagy induction (5,6). Autophagy, from the Greek meaning 'self-eating', is a recycling machinery of intracellular proteins and organelles like mitochondria (7). Macroautophagy is the major type of autophagy and is referred to as autophagy for the remainder of the current study. This process comprises several sequestration steps, beginning with a phagophore enclosing cellular waste and forming the autophagosome by elongation (8). Fusion of the autophagosome and a lysosome allows acidic hydrolases to degrade the inner components of the now termed 'autolysosome' (8).

For the purposes of monitoring the autophagic flux, the microtubule-associated protein light chain 3 (LC3) is one of the most reliable proteins (8). Pro-LC3 is cleaved by the autophagy-related gene 4 (Atg4) to form LC3-I (9). The conjugation of LC3-I to phosphatidylethanolamine forms LC3-II, which is the lipidated form of LC3 and is located at the autophagosome cytosolic and intraluminal membrane (8). Subsequently, LC3-II at the intraluminal membrane is degraded by lysosomal hydrolases in the final step of autophagy (8). The drug chloroquine inhibits this last step, resulting in an accumulation of LC3-II (10).

Beclin-1, the mammalian homolog of Atg6, is required to initiate the autophagic process (11,12). Notably, Wei et al (13) described an interaction between the epidermal growth factor receptor (EGFR) and autophagy in non-small cell lung cancer (NSCLC) cells. Active EGFR inhibited the initiation of autophagy via phosphorylation of Beclin-1, and activation of EGFR was performed through the addition of EGF or by
transfection of cells with the truncated EGFR\textsuperscript{vIII} version (13). This mutated receptor is common in NSCLC cells, as well as in GBM (14,15). Due to an in-frame deletion of exon 2-7, the extracellular binding portion is deleted, leading to the continuous activation of EGFR (15). Wei et al (13) identified that this activation inhibits autophagy through an interaction with Beclin-1 (13). It remains to be established whether the same underlying mechanisms are relevant in GBM.

Materials and methods

Reagents. TMZ and chloroquine were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). EGF was purchased from PeproTech Inc. (Rocky Hill, NJ, USA).

Cell culture and cell treatment. The LN18 human glioblastoma cell line, first characterized in 1981 (16), was obtained from Dr. Van Meir (University of Lausanne, Switzerland). pGBM T1 and pGBM T12 cells were isolated from tissues that were collected in cooperation with the Department for Neurosurgery at Technische Universität München (Munich, Germany). Primary cell culture was established by Dr. Andrea Schäfer as previously described (17). The resection (January and May 2008) and subsequent processing were performed with patients’ consent according to the Technische Universität München medical faculty’s guidelines for tissue preservation. Primary single cell suspensions were only cultured at early passages. The primary glioblastoma stem cell line X01 was obtained from Dr Andreas Androussellis-Theotokis (Carl Gustav Carus University, Dresden, Germany).

LN18, pGBM T1 and pGBM T12 cells were maintained in Dulbecco's modified Eagle's medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) under standard cell culture conditions in the presence of 5% CO\textsubscript{2} at 37°C in a humidified incubator. When treating cells with chemotherapeutics, the concentration of fetal calf serum (FCS; Thermofisher Scientific, Inc.) was reduced from 4 to 0.1% to minimize off-target FCS effects. The primary glioblastoma tumor stem cell line X01 was cultured in RPMI-1640 medium (Thermo Fisher Scientific, Inc.) supplemented with 1% L-glutamine (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 20 ng/ml basic fibroblast growth factor (Thermo Fisher Scientific, Inc.).

LN18, pGBM T1 and pGBM T12 were exposed to 50 µM chloroquine for 2 h. LN18 cells were treated with 20 ng EGF for 30 min. The concentration of TMZ treatment varied from 100-500 µM for 2-72 h due to different responses in established and primary cell lines.

Hypoxic treatment of cells. pGMB X01 cells were placed in the hypoxic incubating chamber at 37°C and O\textsubscript{2} was gradually replaced by nitrogen within 11 cycles. Following incubation for 24 h at 1% O\textsubscript{2}, the cells were lysed at the same time as the normoxic pGBM X01 control cells.

Immunoblotting. Collected and washed LN18, LN18\textsuperscript{vIII}, pGBM T1 and pGBM T12 proteins were resuspended in freshly prepared lysis buffer (20% L-Buffer, 2% phenylmethylsulfonyl fluoride; Cell Signaling Technology, Inc., Danvers, MA, USA) and incubated rotating at 4°C for 10 min. Protein quantification was measured using a Bradford protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Following quantification, equal amounts of proteins (20 µg) were unfolded and charged by the detergent sodium dodecyl sulfate. SDS-PAGE gels were prepared with the permeability (7-12%) adjusted to the size of the proteins. Following separation through the gel matrix, proteins were transferred to an immobilizing polyvinylidene difluoride membrane. Blocking of nonspecific binding sites was performed with 5% milk for 1 h at room temperature. Cells were incubated with the following primary antibodies by rotating at 4°C overnight: Beclin-1 (1:1,000; catalog no. 4445S; Cell Signaling Technology, Inc., Danvers, MA, USA), light chain 3 B-II (LC3B; 1:1,000; catalog no. 4445S; Cell Signaling Technology, Inc.), MGMT (1:1,000; catalog no. 2739; Cell Signaling Technology, Inc.), EGFR Ab-12 cocktail R19/48 (1:500; catalog no. MS-400-P; Thermo Fisher Scientific, Inc.). Cells were incubated with the primary antibodies against EGFR Ab-12 cocktail R19/48 (1:200; catalog no. MS-400-P; Thermo Fisher Scientific, Inc.) and Beclin-1 (1:200; catalog no. SC-11427; WÜRSTLE et al: EGFR INDEPENDENT AUTOPHAGY INDUCTION IN GLIOBLASTOMA 323).

LN18, pGBM T1 and pGBM T12 were exposed to 50 µM chloroquine for 2 h. LN18 cells were treated with 20 ng EGF for 30 min. The concentration of TMZ treatment varied from 100-500 µM for 2-72 h due to different responses in established and primary cell lines.

Immunofluorescence. LN18 and LN18\textsuperscript{vIII} cells were cultured on gelatin-coated glass slips for 48 h prior to TMZ (500 µM) application. At 48 h following treatment, cells were fixed with 4% paraformaldehyde at room temperature for 30 min and washed 3 times with PBS. To allow access to intracellular antigens, cells were exposed to the surfactant 0.1% Triton X-100 (Carl Roth GmbH+Co. KG, Karlsruhe, Germany)/PBS for 10 min. Blocking of unspecific binding sites was conducted with an antibody blocking buffer containing 1% bovine serum albumin (Bio-Rad Laboratories, 0.01% Tween-20 (Carl Roth GmbH+Co. KG) and 2.5% goat-serum (Thermo Fisher Scientific, Inc.) for 30 min at room temperature. The cells were incubated with the primary antibodies against EGFR Ab-12 cocktail R19/48 (1:200; catalog no. MS-400-P; Thermo Fisher Scientific, Inc.) and Beclin-1 (1:200; catalog no. SC-11427; WÜRSTLE et al: EGFR INDEPENDENT AUTOPHAGY INDUCTION IN GLIOBLASTOMA 323).
Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 2 h at room temperature. Following washing with PBS, the cells were exposed to Alexa-568-conjugated anti-mouse (1:500; catalog no. A-11004) and Alexa-488-conjugated anti-rabbit secondary antibodies (1:500; catalog no. A-11008; Thermo Fisher Scientific, Inc.). The cells were subsequently incubated for 45 min at room temperature in the dark. The slides were analyzed with the Axio Imager 1 microscope (Zeiss AG, Oberkochen, Germany).

**Co-immunoprecipitation.** To detect protein-protein interactions, a Pierce Classic immunoprecipitation kit (Thermo Fisher Scientific, Inc.) was used according to the manufacturer’s protocol. The cells were lysed with ice-cold immunoprecipitation lysis buffer and purified by using control agarose resin. The flow-through was prepared in order to form the immune complex with the primary antibody overnight. The complex was captured in a spin column containing resin slurry by gently mixing for 1 h. Following three washing steps, the immune complex was eluted by incubation in 2X non-reducing sample buffer with dithiothreitol (20 mM) and collected by centrifugation at 1,000 g at 4°C for 45 sec. The antibodies against Beclin-1 (immobilization, 1:100; immunoblotting, 1:1,000; catalog no. 3495; Cell Signaling Technology, Inc.) and EGFR (immobilization, 1:100; immunoblotting 1:1,000; catalog no. 2232; Cell Signaling Technology, Inc.) were used. A protein complex can be pulled down with one or two antibodies depending on whether only the interaction is a matter of interest, or the expression of the two individual proteins is being examined (18). In this case, Beclin-1 and EGFR are established as being expressed in LN18 cells (19,20). For that reason, co-immunoprecipitation was performed using Beclin-1 alone for pull-down.

**Statistical analysis.** ImageJ (version 1.51; National Institutes of Health, Bethesda, USA) and Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA, USA) were used for analyzing western blots and immunofluorescence. Relative normalization control values of respective GAPDH lanes were used for normalizing the protein of interest. Statistical analysis of Student's t-test and Pearson's correlation analysis was performed with R Studio (version 3.2.3; R Studio, Boston, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Chloroquine application increases LC3B-II levels.** To assess whether the cell lines in the present study are responsive to autophagy, chloroquine was applied to the established cell line LN18 and the primary lines pGBM T1 and pGBM T12. Fig. 1A and the corresponding analysis (Fig. 1B) indicates the significant increase of LC3B-II levels in chloroquine-treated cells (P<0.05), suggesting a block of autophagy. Beclin-1 was ubiquitous expressed, but its expression levels were not affected by chloroquine treatment.

**TMZ induces autophagy in primary and established glioblastoma cells.** LN18 cells were treated with 100-200 μM TMZ for 2 h each, which did not result in an increase in LC3B-II protein levels (data not shown). Conversely, TMZ treatment (500 μM) for 72 h resulted in a arked upregulation of LC3B-II (Fig. 1C). To investigate these findings with primary cells, pGBM T1 and pGBM T12 cells were exposed to TMZ (200 μM), which resulted in a significant increase of LC3B-II in pGBM T1 cells (Fig. 1D and E; P=0.0168). The primary cell line pGBM T12 exhibited only a minor modification of LC3B-II levels.

**TMZ application decreases MGMT protein levels.** Methylation of the promoter of the MGMT gene and its associated lowered protein levels results in a higher susceptibility towards TMZ treatment (21). LN18 cells expressed high levels of MGMT protein (Fig. 2A). By contrast, pGBM T1 and pGBM T12 did not express MGMT protein (data not shown). The high levels of MGMT in LN18 cells decreased following the application of TMZ (Fig. 2A and B; P<0.05), indicating a reduction in MGMT protein.

**EGFR and EGFRvIII do not phosphorylate Beclin-1 independently of TMZ or EGF application.** In the present study, several techniques were applied to monitor the potential interactions of Beclin-1 and EGFR. Immunoblotting revealed the phosphorylation status of Beclin-1, demonstrating that, in LN18 cells, Beclin-1 was not phosphorylated independently of TMZ application. To minimize the effects of inactive EGFR, LN18 cells transfected with the constitutively active vIII mutant were cultured (Fig. 3A). In addition, LN18 was incubated with EGF (20 ng, 30 min). Beclin-1 phosphorylation status was not divergent from the controls following EGF application or in LN18vIII. LC3B-II levels were not altered in LN18 by stimulation with EGF (Fig. 3B).

**EGFR and EGFRvIII do not co-immunoprecipitate with Beclin-1 independently of TMZ or EGF application.** In the GBM cell lines LN18 and LN18vIII, Beclin-1 and EGFR did not co-immunoprecipitate (Fig. 3C and D). The EGFR-Beclin-1 interaction was not promoted by treatment with TMZ (500 μM, 24 h) or by stimulation with EGF (20 ng, 30 min; Fig. 3D). These results were further confirmed by co-immunoprecipitation of the primary GBM cell line X01. To investigate whether hypoxia, as is present in the center of tumor masses, interferes with the EGFR-Beclin-1 association, pGBM X01 was incubated under hypoxic culture conditions for 24 h. Formation of the EGFR-Beclin-1 complex was not induced by hypoxia for 24 h in X01 cells (data not shown).

**Immunofluorescence detects varied localizations for EGFR and Beclin-1 independent of TMZ application.** Immunofluorescence is a method enabling the visualization of co-localized proteins, suggesting their interaction. As presented in Fig. 4, the majority of EGFR spots could be identified in LN18vIII cells due to the antibody detection of wild-type EGFR, as well as the aberrant form vIII. EGFR and Beclin-1 were not adjacent in LN18 and LN18vIII. This result was not altered by treatment with high-dose TMZ. Compared with LN18vIII expressing the truncated and constitutively active EGFR, TMZ treatment appeared to restrict growth more in wild-type LN18 cells.
Discussion

Previous studies on autophagy have provided insight into its underlying mechanisms at a molecular level (22). However, there remain challenges to our understanding, including the investigation of interacting signaling pathways and their impact on the deleterious or protective character of autophagy. With an inter-disciplinary effort, the elucidation of the interaction between autophagy proteins and other significant cellular pathways may aid the treatment of malignant cancer, including GBM.

GBM is the most malignant type of brain tumor in adulthood and poses a major challenge in terms of therapy.
At present, the alkylating drug TMZ is used as the first-line treatment for primary GBM (1). The heterogeneous character of GBM cells complicates the evaluation of interference of TMZ with various cellular signaling pathways (24). However, the primary influences of TMZ on cellular signaling pathways require elucidation to analyze adverse side effects as well as potential accompanying therapeutic approaches. One affected pathway appears to be the catabolic process of autophagy (5). The conversion of LC3 has now become the most widely used method to monitor autophagy (8). An increase of LC3B-II, as presented in Fig. 1A, may be induced in primary and established GBM cell lines by autophagy regulation using chloroquine. This drug inhibits the fusion of lysosomes with autophagosomes, resulting in an accumulation of LC3B-II (10). Chloroquine has been used in several studies to suppress tumor growth, including in lung cancer cells (25). In GBM, the effects of chloroquine were promising and led to a significant extension of overall patient survival time (26).

Primary cell culture, which is an improved mimicry of relevant \textit{in vivo} conditions, was compared to established GBM cell lines, as they are hypothesized to vary in dedifferentiation (27). The investigated primary cell lines pGBM T1 and pGBM T12 did not express MGMT, in contrast to LN18. The findings of the current study indicate that autophagy is increased in primary cell lines, predominantly in pGBM T1, by a lower concentration of TMZ and reduced treatment time compared with the established cell line LN18. The positive regulation of TMZ on autophagy may be interpreted as a response to adverse cellular conditions (5). The LN18 cells were not affected by low dose and short-term treatment with TMZ in the present study, which indicates TMZ-resistant characteristics. However due to adverse side effects, the high dose of TMZ required for autophagy induction in LN18 is not feasible for use in patients with resistant GBM. Taken together, this process of hindering cells from escaping adverse cellular

Figure 3. EGFR and Beclin-1 do not interact directly by phosphorylation. (A) Wild-type and truncated EGFR was detected using western blotting. The truncated vIII form was observed at ~145 kDa. (B) EGF application to LN18 cells did not modify LC3B-II levels. (C) EGFR and Beclin-1 do not bind in LN18 cells. Immunoblotting of Co-IP reveals the pull-down of EGFR in the first lane, the pull-down of Beclin-1 in the second lane and the original lysate in the final lane. Beclin-1 antibody caused a smear in all Co-IP blots. This blurred spot was observed at a lower position compared with Beclin-1 in the blot. (D) EGFR and Beclin-1 do not interact following treatment with EGF. Cells were previously treated with EGF (20 ng/ml, 30 min) and Co-IP was performed by pull-down of Beclin-1. EGFR, epidermal growth factor receptor; LC3B-II, light chain 3 B-II; Co-IP, co-immunoprecipitation; EGF, epidermal growth factor.

Figure 4. Immunofluorescence double-labeling of Beclin-1 (red) and EGFR (green). (A) GBM cell line LN18, (B) GBM cell line LN18+TMZ, (C) GBM cell line LN18vIII and (D) GBM cell line LN18vIII+TMZ. Magnification, x63. Microphotographs reveal Beclin-1 protein expression at similar levels in the two cell lines, whereas LN18vIII expresses higher levels of EGFR. EGFR and Beclin-1 are not directly adjacent to one another. (E) Intensity of green and red pixels were identified per cell and analyzed for colocalization with the plugin ‘colocalization colormap’ in ImageJ. The scatterplot reflects the lack of correlation by the two separate groups of points. This was verified for each cell line and each condition. Pearson's correlation coefficient (pixel-by-pixel covariance): 0.39 (LN18), 0.00 (LN18+TMZ), 0.01 (LN18vIII) and -0.06 (LN18vIII+TMZ). (F) Results of an analysis of 6 different immunofluorescence images of each cell line of one experiment. EGFR, epidermal growth factor receptor; LN18vIII, constitutively active EGFRvIII variant, TMZ, temozolomide.
conditions using chloroquine may be a promising addition to TMZ treatment.

Another established underlying mechanism to circumvent TMZ-induced damages is MGMT, which removes methylated DNA adducts (4). The expression of MGMT is a negative predictive factor for survival time in patients with GBM (28). In the current study, LN18 cells expressed MGMT, but the protein levels were markedly decreased by TMZ (Fig. 2). This indicates that the cellular supply of MGMT is exhausted when repairing methylated TMZ lesions, concordant with the findings of Wick et al (29). The primary cell lines pGBM T1 and pGBM T12 did not express MGMT, which may be interpreted as favorable regarding TMZ treatment.

The transmembrane signaling module EGFR serves a significant role in numerous cellular signaling pathways and its amplification or mutations are encountered in numerous cases of GBM, the most common of which is EGFRvIII (15). Lacking its outer regulative portion, EGFRvIII provides constant signaling for the tumor cell (14). This signaling not only enhances phosphoinositide 3-kinase/protein kinase B activation, but also appears to possess divergent characteristics compared with wild-type EGFR signaling (30,31). In the present study, the expression of the truncated vIII form appeared to be linked to higher resistance towards high-dose application of TMZ in LN18, as detected by immunofluorescence (Fig. 4). Notably, the co-expression of wild-type and truncated EGFR, as with LN18vIII, is hypothesized to result in an antagonistic connection between the two receptors (32). This may induce malignancy in GBM (32). However, the prognostic role of the truncated version of EGFR remains controversial. Shinojima et al (33) identified a poor prognostic outcome in patients with GBM due to EGFRvIII in combination with EGFR amplification. By contrast, Montano et al (34) revealed a prolonged survival for patients with GBM expressing EGFRvIII (34). The altered signaling function of EGFRvIII and its implication in GBM growth and therapy resistance must be investigated in detail in the future.

Wei et al (13) suggested an important role for EGFR in the inhibition of autophagy initiation (13). This previous study described the phosphorylation of Beclin-1 by active EGFR in NSCLC cells (13). If EGFR in GBM cells also regulates Beclin-1, this is of note as EGFR is frequently amplified or mutated in GBM (35). In the current study, Beclin-1 was not phosphorylated by inactive or active EGFR independently of TMZ treatment in LN18 and LN18vIII. GBM cells did not exhibit modification of autophagy monitored by wild-type EGFR, application of EGFR or EGFRvIII. Beclin-1 did not bind to EGFR or EGFRvIII in control cells or TMZ-treated cells in established and primary GBM. The interaction between Beclin-1 and EGFR remained unaffected by hypoxic conditions for 24 h. Immunofluorescence revealed that Beclin-1 locations are not directly adjacent to EGFR locations in LN18 or LN18vIII, which did not vary upon TMZ application. These data demonstrate that Beclin-1 does not interact directly with EGFR in the GBM cell lines used in the present study and suggests varied regulation, particularly for primary GBM culture. This is concordant with Zhu and Shah (36), suggesting other regulative pathways for autophagy than EGFR in GBM.

Further studies may focus on the interaction between inactive EGFR and autophagy. Tan et al (37) demonstrated that a knockdown of EGFR inhibited autophagy in different cell lines, but this study did not include brain tumor cells (37). However, these findings are in favor of an important stimulus of autophagy by inactive EGFR in certain tumor entities, and may be evaluated in GBM cells.

Acknowledgements

The authors would like to thank Dr Andreas Androushellis-Theotokis (Carl Gustav Carus University, Dresden, Germany) for the cell line X01, Dr Daniela Schilling (Department of Radiooncology Technische Universität, Munich, Germany) for providing the hypoxia-incubating chamber and Mrs. Sandra Bau (Department of Neuropathology, Technische Universität, Munich, Germany) for technical support in the laboratory. This work was supported by the Deutsche Forschungsgemeinschaft (SFB 824: ‘Imaging for the Selection, Monitoring, and Individualization of Cancer Therapies’, Project B6).

References


